Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Trovafloxacin

M Haria1, H M Lamb

  • 1Adis International Limited, Auckland, New Zealand.

Drugs
|September 1, 1997
PubMed
Summary
This summary is machine-generated.

Trovafloxacin, a potent fluoroquinolone antibiotic, demonstrates broad-spectrum activity against Gram-negative and Gram-positive bacteria, including resistant strains. Clinical data suggest efficacy in treating various infections, though dizziness is a common side effect.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Levetiracetam.

CNS drugs·2013
Same author

131I tositumomab.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Cladribine: a review of its use in multiple sclerosis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Mizolastine: a review of its use in allergic rhinitis and chronic idiopathic urticaria.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Denileukin diftitox.

American journal of clinical dermatology·2001
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Microbiology
  • Infectious Diseases

Background:

  • Trovafloxacin is a novel fluoroquinolone antibiotic.
  • Fluoroquinolones are a class of synthetic broad-spectrum antibacterial drugs.

Purpose of the Study:

  • To evaluate the antibacterial spectrum of trovafloxacin.
  • To compare its activity with ciprofloxacin.
  • To assess preliminary clinical efficacy and safety.

Main Methods:

  • In vitro susceptibility testing against various bacterial pathogens.
  • Comparison of minimum inhibitory concentrations (MICs) with ciprofloxacin.
  • Review of preliminary clinical trial data for efficacy and adverse events.

Main Results:

Related Experiment Videos

  • Trovafloxacin exhibits broad-spectrum activity against Gram-negative and Gram-positive bacteria.
  • It shows enhanced activity (2- to 8-fold) against staphylococci and streptococci compared to ciprofloxacin.
  • Activity includes methicillin-resistant staphylococci and penicillin-resistant Streptococcus pneumoniae.
  • Preliminary clinical data indicate effectiveness in respiratory and urinary tract infections, and STIs.

Conclusions:

  • Trovafloxacin possesses a broad antibacterial spectrum, including activity against resistant pathogens.
  • It demonstrates superior in vitro activity against Gram-positive bacteria compared to ciprofloxacin.
  • Preliminary clinical data support its use for specific infections, with dizziness as a notable adverse event.